KALV: KalVista Pharmaceuticals Inc Price to Sales
KalVista Pharmaceuticals is developing innovative tablets for the therapy of rare immune pathologies, replacing injections with oral medications. Monitoring the company's P/S ratio helps assess the issuer's market value relative to revenue, where the value of 966.80 expresses the metric level. However, the business relies on a single product, creating a niche dependency. Prospects are limited by clinical trial risks and the need for additional capital.
KalVista Pharmaceuticals (KALV) - metric breakdowns and financial figures
- stock price and consensus target price:
- market capitalization information:
- shareholders' equity book value data:
- issuer credit burden and liquidity indicators:
Debt to Equity KalVista Pharmaceuticals|KALV - Long-Term Debt to Equity Ratio|Short-Term Debt to Equity KalVista Pharmaceuticals|KALV - Company Aggregate Debts|Debts to Net Assets KalVista Pharmaceuticals|KALV - Company Long-Term Debt|Short-Term Debt Volume KalVista Pharmaceuticals|Intermediate Liquidity Ratio kalvista.com
- company profitability and valuation multiples indicators:
KALV - Net Profit|Projected Future Earnings KalVista Pharmaceuticals|KALV - Price to Earnings Ratio|Future Price to Earnings Multiple KalVista Corp|KALV - Price/Earnings to Growth Ratio|Company Value to Operating Income Before Depreciation Ratio KalVista Corp|KALV - Operating profit EBITDA|Earnings per share for the trailing year KalVista Pharmaceuticals|KALV - Net earnings per share (EPS TTM)|Quarterly EPS earnings growth kalvista.com|KALV - Earnings per share growth in current year|Expected earnings per share trend next year KalVista Pharmaceuticals
- issuer revenue and sales details:
General company analysis:KALV, KalVista Pharma
The P/S multiple compares market capitalization to annual revenue, allowing for an assessment of the value of each unit of sales and the identification of an overbought asset. By analyzing the revenue multiple level, an investor can evaluate the extent to which market expectations for KalVista Pharmaceuticals (KALV) are inflated, considering the colossal costs of clinical trials and the high protection of its innovative developments in the rare disease sector.
Competitors of KalVista Pharmaceuticals
argenx - Market Cap to Revenue Ratio|P/S Multiple BNTX (biontech.de)|Abivax Corp (ABVX) - Price to Sales|ADMA Corp - P/S Multiple|Price-to-Sales Ratio PTGX|Immunovant Inc (IMVT) - Price-to-Revenue Ratio|KNSA - Price-to-Revenue Coefficient|GRFS (Grifols Biemat) - P/S Multiple|P/S Multiple Adaptive Biotechnologies Inc.|Price-to-Revenue Ratio Celldex Therapeutics (CLDX)|Price-to-Revenue Coefficient auriniapharma.com|Price-to-Revenue Ratio BioCryst Pharmaceuticals BCRX|Market Capitalization-to-Revenue Ratio VERA|Dianthus Pharma - P/S Multiple|PHVS - P/S Multiple|ABCL: P/S Multiple|TRML (Tourmaline Bio, Inc.) - Price-to-Revenue Ratio|Price-to-Revenue Ratio Intrexon|PHAR - Price-to-Revenue Multiple|P/S Multiple NKTR|Price-to-Revenue Ratio UPB (Upstream Bio Corp)|Price-to-Revenue Ratio Zenas Biopharma, Inc. ZBIO|Price-to-Revenue Coefficient immunome.com (IMNM)|Gossamer Bio Inc - P/S Multiple|SEPN (Septerna) - Market Cap to Revenue Ratio|Pieris Corp (PVLA) - Price-to-Revenue Ratio|SVRA - Price-to-Revenue Coefficient|RIGL (rigel.com) - P/S Multiple|Market Cap to Revenue Ratio ANAB (AnaptysBio, Inc.)|P/S Multiple ATXS|enGene Holdings Inc (ENGN) - Price-to-Revenue Multiple|P/S Multiple RAPT (RAPT Therapeutics Inc.)|JBIO (Aerovate) - Price-to-Sales Ratio|ACRS: Market Cap to Revenue|KYTX - P/S Multiple|TLSA: P/S Multiple|Market Cap to Revenue Cabaletta Bio, Inc|Price-to-Revenue Ratio Ventyx Biosciences, Inc|THTX: Market Capitalization-to-Revenue Ratio|Market Cap to Revenue AVTX (Avalo Therapeutics, Inc)|Market Cap to Revenue Eledon Pharmaceuticals ELDN|Price-to-Revenue Ratio Agenus, Inc. AGEN|P/S Multiple Climb Bio Inc. CLYM|ZURA - Price-to-Revenue Ratio|Price-to-Sales Ratio ATYR|ADAG (Adagene Inc.) - Market Cap to Revenue|ImageneBio Inc (IMA) - P/S Multiple|Price-to-Revenue Ratio Shattuck Therapeutics|Market Cap to Revenue equilliumbio.com (EQ)|P/S Multiple CNTB|Price-to-Revenue Coefficient Immunic Therapeutics|P/S Multiple ATRA (Atara Biotherapeutics, Inc.)|IFRX - Market Cap to Revenue|Market Capitalization-to-Revenue Ratio X4 Pharmaceuticals, Inc. (XFOR)|ACET (adicetbio.com) - Market Cap to Revenue Ratio|CELU: P/S Multiple|INMB - Price-to-Revenue Coefficient|Price-to-Revenue Ratio Barinthus Biotherapeutics plc|KZR: Market Capitalization-to-Revenue Ratio|P/S Multiple SABS|AKTX (Akari Therapeutics Plc) - Market Capitalization-to-Revenue Ratio|P/S Multiple ENLV (Enlivex Therapeutics Ltd)|q32bio.com - Price-to-Revenue Ratio|GOVX: Market Cap to Revenue|edesabiotech.com (EDSA) - Market Cap to Revenue|IBIO: P/S Multiple|CARM - Price-to-Revenue Coefficient|Market Cap to Revenue XTLB|Market Cap to Revenue boltbio.com (BOLT)|Price-to-Revenue Ratio HCW Biologics Inc (HCWB)|P/S Multiple Aptevo Therapeutics, Inc. (APVO)|Price-to-Revenue Ratio aimimmuno.com AIM|Market Capitalization-to-Revenue Ratio ADTX|GRI Bio Corporation - P/S Multiple|XORTX Corp (XRTX) - Market Cap to Revenue|HIND (Vyome Holdings Inc.) - Market Cap to Revenue|revbiosciences.com (REVB) - P/S Multiple|INDP (Indaptus Corp) - P/S Multiple|Market Cap to Revenue Scinai Immunotherapeutics Ltd (SCNI)|Price-to-Revenue Ratio CalciMedica Inc (CALI)|AFMD (Affimed NV) - Market Capitalization-to-Revenue Ratio|P/S Multiple ALLK (Allakos Inc.)|P/S Multiple HOOKIPA HOOK|IGMS: Market Cap to Revenue|Market Capitalization-to-Revenue Ratio ITOS (iTeos)|OCEA: P/S Multiple|TCBP (TC BioPharm Ltd) - Price-to-Revenue Ratio|THRD (Third Harmonic Bio Inc) - P/S Multiple
